Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Modra Pharmaceuticals B V has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. The busiest examiner, DAVIS, BRIAN J, is responsible for 1 pending action, showing an even distribution of work.
Each of the 2 pending office actions is being handled by a different examiner in a different art unit, showing no overlap in the current prosecution personnel. This 1 to 1 ratio between actions and examiners indicates that there is no concentration of cases under a single point of contact. With 1 busiest examiner pending action, the workload is decentralized across the 2 distinct examiners and 2 distinct art units.
Practitioners must manage 2 separate examiner relationships, as no two pending actions share the same examiner. The 2 distinct art units involved suggest that the company's biotechnology and pharmaceutical innovations fall under different technical classifications. This structure requires a unique prosecution approach for each of the 2 pending office actions, as there is no central examiner or art unit to provide a consistent baseline for comparison.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19066854 | Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels | DAVIS, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838206 | METHODS AND COMPOSITIONS FOR TREATING CANCER IN TAXANE-RESISTANT PATIENTS | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19066854 | Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels | DAVIS, BRIAN J | 1614 | §102 | Non-Final OA | — | Pending | Feb 28, 2025 |
| 18838206 | METHODS AND COMPOSITIONS FOR TREATING CANCER IN TAXANE-RESISTANT PATIENTS | HAVLIN, ROBERT H | 1626 | §102§103DP | Non-Final OA | — | Pending | Aug 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialModra Pharmaceuticals B V has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brian J Davis has the most, with 1 of Modra Pharmaceuticals B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
